291 related articles for article (PubMed ID: 21041718)
1. Codon optimization of human factor VIII cDNAs leads to high-level expression.
Ward NJ; Buckley SM; Waddington SN; Vandendriessche T; Chuah MK; Nathwani AC; McIntosh J; Tuddenham EG; Kinnon C; Thrasher AJ; McVey JH
Blood; 2011 Jan; 117(3):798-807. PubMed ID: 21041718
[TBL] [Abstract][Full Text] [Related]
2. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
Kootstra NA; Matsumura R; Verma IM
Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
[TBL] [Abstract][Full Text] [Related]
3. Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia A.
Johnston JM; Denning G; Doering CB; Spencer HT
Gene Ther; 2013 Jun; 20(6):607-15. PubMed ID: 22996197
[TBL] [Abstract][Full Text] [Related]
4. Expression and characterization of a codon-optimized blood coagulation factor VIII.
Shestopal SA; Hao JJ; Karnaukhova E; Liang Y; Ovanesov MV; Lin M; Kurasawa JH; Lee TK; Mcvey JH; Sarafanov AG
J Thromb Haemost; 2017 Apr; 15(4):709-720. PubMed ID: 28109042
[TBL] [Abstract][Full Text] [Related]
5. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
[TBL] [Abstract][Full Text] [Related]
6. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
8. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
[TBL] [Abstract][Full Text] [Related]
9. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
11. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
[TBL] [Abstract][Full Text] [Related]
12. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
15. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.
Matsui H; Fujimoto N; Sasakawa N; Ohinata Y; Shima M; Yamanaka S; Sugimoto M; Hotta A
PLoS One; 2014; 9(8):e104957. PubMed ID: 25126862
[TBL] [Abstract][Full Text] [Related]
16. Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.
Zhu F; Liu Z; Miao J; Qu H; Chi X
Sci China Life Sci; 2012 Jun; 55(6):521-6. PubMed ID: 22744182
[TBL] [Abstract][Full Text] [Related]
17. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.
Doering CB; Denning G; Dooriss K; Gangadharan B; Johnston JM; Kerstann KW; McCarty DA; Spencer HT
Mol Ther; 2009 Jul; 17(7):1145-54. PubMed ID: 19259064
[TBL] [Abstract][Full Text] [Related]
18. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.
Scallan CD; Liu T; Parker AE; Patarroyo-White SL; Chen H; Jiang H; Vargas J; Nagy D; Powell SK; Wright JF; Sarkar R; Kazazian HH; McClelland A; Couto LB
Blood; 2003 Dec; 102(12):3919-26. PubMed ID: 12893764
[TBL] [Abstract][Full Text] [Related]
20. Recombinant expression of coagulation factor VIII in hepatic and non-hepatic cell lines stably transduced with third generation lentiviral vectors comprising the minimal factor VIII promoter.
Picanço V; Heinz S; Bott D; Behrmann M; Covas DT; Seifried E; Tonn T
Cytotherapy; 2007; 9(8):785-94. PubMed ID: 17917890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
